Results 51 to 60 of about 704 (128)
CPT: Pharmacometrics &Systems Pharmacology, Volume 13, Issue 4, Page 673-685, April 2024.Abstract Tuberculosis (TB) is a life‐threatening infectious disease. The standard treatment is up to 90% effective; however, it requires the administration of four antibiotics (isoniazid, rifampicin, pyrazinamide, and ethambutol [HRZE]) over long time periods.
Maral Budak +7 more
wiley +1 more source
Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic [PDF]
, 2021 The WHO 2020 global TB Report estimates that in 2019 there were an estimated 500,000 cases of multi-drug resistant TB (MDR-TB) of which only 186,772 MDR-TB cases were diagnosed, and positive treatment outcomes were achieved in 57% of them.
Galvin, J +5 more
core
Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches [PDF]
, 2017 Peptides of varied origins such as human immune cells and non-immune cells, bacteria, fungi, and venoms have been widely investigated as anti-tubercular agents for the replacement of existing anti-tubercular drugs in future.
Aarti, Chirom +7 more
core
2016 Pipeline Report Tuberculosis Edition [PDF]
, 2016 Over the past decade, several new options for improving TB diagnosis have become available. The past year saw considerably more progress than the previous one. However, the reality of how most TB is diagnosed—or not—remains largely unchanged.
Erica Lessem +2 more
core
Classifying new anti-tuberculosis drugs: Rationale and future perspectives [PDF]
, 2016 The classification of anti-tuberculosis (TB) drugs is important as it helps the clinician to build an appropriate anti-TB regimen for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases that do not fulfil the criteria for the shorter ...
Caminero Luna, JA +10 more
core
Gene expression responses to anti-tuberculous drugs in a whole blood model. [PDF]
, 2020 BACKGROUND: There is a need for better tools to evaluate new or repurposed TB drugs. The whole blood bactericidal activity (WBA) assay has been advocated for this purpose.
De Sessions, Paola Florez +6 more
core +1 more source
2016 Pipeline Report HIV and TB [PDF]
, 2016 HIV and TB: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in ...
Erica Lessem +7 more
core
Infection and Drug Resistance, 2023 Tianhui Gao,1,* Cong Yao,1,* Yuanyuan Shang,1 Renchun Su,1 Xuxia Zhang,1 Weicong Ren,1 Shanshan Li,1 Wei Shu,2 Yu Pang,1 Qi Li2 1Department of Bacteriology and Immunology, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing ...
Gao T +9 more
doaj
Optimising linezolid use for drug-resistant tuberculosis: pharmacokinetics, toxicity, and resistance [PDF]
, 2022 Background: Rifampicin-resistant tuberculosis (RR-TB) accounts for an expanding proportion of incident global TB cases and is a major barrier to global tuberculosis control. There is a need for more effective, safe, and well-tolerated drugs. Linezolid is
Wasserman, Sean Adam
core +1 more source
Tuberculosis 110 years after the Nobel Prize awarded to Koch [PDF]
, 2015 Robert Koch recibió el Premio Nobel por sus investigaciones y descubrimientos sobre la tuberculosis (TB) en 1905. Descubrió su agente causal, describió los cuatro postulados que guiaron desde entonces las investigaciones en enfermedades transmisibles y ...
Kantor, Isabel N. +1 more
core